title: REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation--The RELIEF study.
authors.affiliation: University of Connecticut School of Pharmacy, Storrs, CT, USA. Electronic address: craig.coleman@hhchealth.org.
authors.forename: Craig I
authors.initials: CI
authors.lastname: Coleman
authors.affiliation: Hospital Oldenburg, Department of Cardiology, Oldenburg, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Antz
authors.affiliation: IMS Health, Munich, Germany.
authors.forename: Birgit
authors.initials: B
authors.lastname: Ehlken
authors.affiliation: Bayer Pharma AG, Wuppertal, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Evers
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000150:complications*; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*
chemical_list: D065427:Factor Xa Inhibitors
keywords: Anticoagulant; Non-valvular atrial fibrillation; Rivaroxaban; Stroke; Vitamin k antagonist